TNFRSF10B and cancer: In contrast to dulanermin, which has a short bioavailability of 30 min, which requires daily treatment for patients and the inability to bind to death‐inducing TRAIL receptors in various cancer types, preferring to bind with the decoy TRAIL receptors 35, 36, drozitumab is a fully agonistic human monoclonal antibody that specifically binds to and activates DR5 in the same manner as dulanermin 24.